

REMARKS


The Examiner restricted the claims into three groups: Group 1 (Claims 24-27) directed toward treating HIV infections with an integrase inhibitor, a reverse transcriptase inhibitor, and a protease inhibitor; Group II (Claims 28-32) directed toward treating HIV infections that are at least partially resistant to reverse transcriptase inhibitors employing an integrase inhibitor and an RT inhibitor; and Group III (Claims 33-38) directed toward treating HIV infections that are at least partially resistant to reverse transcriptase inhibitors employing an integrase inhibitor and a protease inhibitor. Applicants hereby elect Group II (Claim 28-32) without traverse. Applicants have cancelled Claims 24-27 and 33-38 without prejudice. The Examiner also requested a species election for Group II, designating one integrase inhibitor and one RT inhibitor.

Applicants hereby designate L-Chicoric acid as the integrase inhibitor, which reads on Claims 28-32, and Applicants designate zidovudine as the RT inhibitor, which reads on Claims 28-30.

CONCLUSION

If the Examiner wishes to discuss this case, Applicants encourage the Examiner to call the undersigned at 608-218-6900 at the Examiner's convenience.

Dated: February 21, 2007



Jason R. Bond
Registration No. 45,439
MEDLEN & CARROLL, LLP
101 Howard Street, Suite 350
San Francisco, California 94105